GSK Hematology
Myelofibrosis
GSK Hematology
Findings from a Phase 3 Head-to-Head Myelofibrosis Study
FEATURING
Salman Fazal
- July 17, 2025
GSK Hematology
Assessing the Safety Profile of a JAK Inhibitor in Myelofibrosis
FEATURING
Karolina Faysman
- July 17, 2025
GSK Hematology
Dosing and Administration Information for a JAK Inhibitor in Myelofibrosis
FEATURING
Mark Davis
- July 17, 2025
GSK Hematology
Overview of an Approved Myelofibrosis Treatment Option
FEATURING
Hana Safah
- July 17, 2025